Patrick Daly

Cancer Nursing Today nonprod

A trial examined weekly administration of LCL161 therapy in a large, high-risk, older study population with myelofibrosis (MF), and found that it appears to be a safe and effective treatment option. The phase II trial was led by Naveen Pemmaraju, MD, and colleagues. Their findings were published in Blood Advances.Noting that JAK inhibitors are largely contraindicated in some patients, such as those with severe thrombocytopenia, the authors suggested that &ldquo;there is an unmet medical need for the development of novel agents for patients with MF.&rdquo;The study comprised of a single-center trial with LCL161 (oral, starting dose, 1500 mg per week) administered to patients with intermediate- to high-risk MF. In the analysis, 66% of subjects had two or more prior therapies, and a median baseline platelet count of 52 &times; 103/?L, with 28% having ASXL1 mutations. Observers noted a 30% objective response. Notably, six patients achieved clinical improvement of anemia, four achieved hemoglobin response, and two achieved transfusion independence. The median overall survival (OS) was 34 months (range: 2.2 &ndash; 60.1+), and cIAP protein reductions were observed in all responders.The most common toxicities reported in patients were: nausea/vomiting (64%, mainly grade I or II), fatigue (46%), and dizziness/vertigo (30%). There were four grade III or IV adverse events (two, syncope; one, nausea/vomiting; one, skin eruption/pruritis) observed in the study.Researchers concluded that LCL161 exhibited safe and effective outcomes. Moreover, given the need for treatments beyond JAK inhibitors, the authors suggested that SMAC mimetics, like LCL161, may be a viable option for certain patients.

LCL161 in Treating Patients With Myelofibrosis: Phase II Trial Results

Myelofibrosis

A trial examined weekly administration of LCL161 therapy in a large, high-risk, older study population with myelofibrosis (MF), and found that it appears to be a safe and effective treatment option. The phase II trial was led by Naveen Pemmaraju, MD, and colleagues. Their findings were published in Blood Advances. Noting that JAK inhibitors are [...]

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe